Robert Turner

Balloon occlusion testing for non-sinus-stenosis venous pulsatile tinnitus: A technical case series

Aaron Brake, Sivani Lingam, Vince Galate, Robert Turner et autres

IntroductionPulsatile tinnitus (PT) affects ∼ 10% of the population and can be debilitating. Venous etiologies of PT are increasingly recognized. Identifying the symptomatic vessel, particularly with multiple venous anomalies, remains challenging.MethodsIn this case series, we utilized venous balloon occlusion testing (vBOT) as …

us (code pays fourni par la source)

MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC

Samantha Novello, Ying Cheng, David R. Spigel, Jian Fang et autres

it, cn, us, jp, kr, es, de, tw, tr, vn, nl, gb, ch (code pays fourni par la source)

Donation after circulatory death: a narrative review of current controversies, attitudes, and the evolving role of regional perfusion technology

James O’Rourke, Gillian-Genevieve Crowe, Robert Turner, Alan Gaffney

Background and Objective: The goal for healthcare professionals in organ donation is to honour the wishes of the donor patient. Securing the best outcome from their altruistic gift to others is central to this goal. This must be achieved in the context …

Safety of non-cuffed tunneled central venous catheters in adults with cystic fibrosis

Arshan Dehbozorgi, Mohamad Badr Jandali, Robert Turner, Aaron Rohr et autres

BACKGROUND: Peripherally inserted central catheters (PICCs) are the most common route of intravenous (I.V.) access for treatment of cystic fibrosis (CF) pulmonary exacerbations, but repeated PICC placement can result in upper extremity peripheral venous stenosis. Once peripheral stenosis develops, a non-cuffed tunneled …

us (code pays fourni par la source)

Abstract 019: Effective Diagnostic Testing For Uncommon Etiologies Of Venous Pulsatile Tinnitus

Sivani Lingam, Aaron Brake, Vince Galate, Robert Turner et autres

Introduction Pulsatile Tinnitus (PT) is a rhythmic sound in the ears. It can be incapacitating and is even associated with depression and suicidal ideationi. The etiology of PT can be grouped into vascular and non‐vascular causes. ii,iii While prominent venous structures may …

us (code pays fourni par la source)

Abstract 3666: Diagnostic application of novel ACE technology: Treatment response monitoring via quantification of cell-free DNA (cfDNA) in plasma from late-stage cancer patients

Robert Kovelman, Juan Pablo Hinestrosa, Delia Ye, Patrick Desmond et autres

Abstract We have developed a novel microfluidic technology that makes use of Alternating Current Electrokinetics (ACE) to isolate macromolecules such as high-molecular-weight DNA and protein complexes as well as nanoparticles, including cell-derived exosomes. As one of the first applications of this novel …

us (code pays fourni par la source)

MP44-02 CHANGING TRENDS IN THE USE OF CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER IN THE UNITED STATES

Mina Fam, Jonathan G. Yabes, Nathan Hale, Robert Turner et autres

INTRODUCTION AND OBJECTIVES: Broad consensus holds that patients with low-risk non-muscle invasive bladder cancer (NMIBC) should undergo less frequent cystoscopic surveillance than those with high-risk NMIBC.We sought to classify surveillance patterns for low-vs.high-risk patients across facilities to assess the extent of risk-aligned …

us (code pays fourni par la source)

MP06-11 SMALL CELL BLADDER CANCER: CONTEMPORARY TREATMENT OUTCOMES INCLUDING PROPHYLACTIC CRANIAL IRRADIATION IN SELECT PATIENTS

Tara Nikonow, Timothy D. Lyon, Robert Turner, Jodi K. Maranchie et autres

and therapeutic response as it takes into consideration tumor heterogeneity.

Abstract 4525: The impact of chemoimmunotherapy dose intensity in diffuse large b-cell lymphoma

Michael P. Chu, Sunita Ghosh, Andrew Belch, Neil Chua et autres

Abstract Introduction Chemotherapy dose intensity (DI) impacts outcomes across tumor subtypes. In diffuse large B-cell lymphoma (DLBCL), DI played a large role prior to rituximab, but is still a subject of investigation. Research into intensifying treatment for poorer prognostic lymphoma subtypes has …

ca (code pays fourni par la source)

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

John Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda Foltz et autres

Abstract Background: Janus kinases (JAKs), including JAK1 and JAK2, mediate the signaling of cytokines and growth factors implicated in the pathogenesis of myelofibrosis (MF). Suppression of JAK2 leads to cytopenias due to its involvement in the signaling pathways of thrombopoietin and erythropoietin. …

us, ca, au (code pays fourni par la source)

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, Bingshu E. Chen, Stephen Couban, C. Tom Kouroukis et autres

Abstract Background: The addition of rituximab (R) to salvage chemotherapy has been shown to improve response rates and proportion of patients subsequently transplanted with Aggressive CD 20+ Non-Hodgkin Lymphoma who were previously R naïve. It is unknown if this benefit would be …

ca, it (code pays fourni par la source)

Progressive vs Non-Progressive Onset of Chronic GVHD After ATG Prophylaxis Is Highly Predictive of Outcome

David T. Jones, Muhd Zanapiah Zakaria, Maggie Yang, Loree Larratt et autres

The NIH chronic graft versus host disease (cGVHD) consensus statement emphasizes the importance of distinguishing acute from cGVHD based on clinical features rather than time. The proposed assessment of cGVHD severity appears to be prognostically important, but the relevance of categories and …

ca (code pays fourni par la source)